Member Info for daveycaferacer

Most Brokers (mine is AJ Bell) will not credit anything to your account until the shares are listed and tradeable.

For those who haven't heard of it, The Pharma Letter is an online publication with daily updates aimed at the Bopharma Community , as opposed to the investment community. It is widely read by those in the industry so it's good to see some coverage of Tiziana today.

Sorry, it's subscription only, but thought it worth posting the link so people are aware this will get read by many who work in the sector.

https://www.thepharmaletter.com/article/tiziana-life-sciences-collaborates-with-parexel-biotech?mc_cid=add354520f&mc_eid=6b5f0b8b96

I think Chi-Med have considerable expertise in the China approval process. Maybe it's taking a little longer because they are also trying to get it on the next updated NDRL at launch? To your point about manufacturing Jatw, I agree, and we have all the required GMP certifications so that should be a formality.

"Ten-baggers Synairgen PLC (LON:SNG) and Tiziana Life Sciences PLC (LON:TILS), which are both developing treatment for COVID-19, also suffered falls and a partial recovery thereafter."

How have they calculated Tiziana Life Sciences is a "Ten bagger!"!!

I think all Institutional Investors including those who invested as part of the recent placing at 200p know exactly what they are doing, will have carried out diligent research and probably had discussions with the Company's Management prior to investing. They are also long term investors.

To be fair, the Board are not interested in short term share price movements (day, week, month, year), they are building an innovate Biopharma that delivers value to patients and long-term Shareholder value.

I doubt they even know what the share price is, or care, and that's the way it should be. True value will play out eventually.

Q4 2020 for both

"2 years for results" and long term experienced Biopharma Investors will know that is very very quick!

10th Nov - CEO Kunwar Shailubhai speaks to Proactive's Andrew Scott following the news they're collaborating with Parexel Biotech to conduct a global Phase 1b/2 trial with enteric-coated capsules of formulated Foralumab

https://youtu.be/M5cQTFJfZtc

New Drug Application - No, if only!
Non Disclosure Agreement with a 3rd party - probably

Eli Lilly announcement today regarding their antibody, however it is not fully human and needs to be adminstered by IV

Meanwhile Pfizer/Biontech's vaccine breakthrough raises hopes, poses logistical headache, needs to be stored at a very low temperature and according to a number of sources will take up to 2 years to rollout to a substantial amount of the world's population.

So vaccines aside, and there is more vaccines on the way, an effective antibody treatment that is easy to self-adminster (eg. not IV ) is still going to required and Foralumab fits that brief perfectly.

Despite what the media and stock markets think, Covid-19 is going to disappear by xmas!

"Based on current projections we expect to produce globally up to 50 million vaccine doses in 2020 and up to 1.3 billion doses in 2021." - Pfizer

That is nowhere near what is needed and the world's population is currently 7.8 billion

An effective antibody treatment will still be required for a number of years

The Company's Corporate presentation has been updated

https://www.chi-med.com/wp-content/uploads/2020/11/pre201105_corp.pdf

good posts shiraz and oldapache

I bought HCM 10 years ago and it's gone up 10 fold, so I will be holding Tiziana for 10 years also. There are so many positives for a company with such a small mcap in the Biotech space, especially around the IP and the Phase 2 trials. Foralumab and Milciclib have so much potential and they are in the clinic as we speak, with Phase 2 trials underway and Phase 3 trials for certain indications under planning. The Covid potential is unexpected and could be extremely material if the Brazil data is positive.

Biopharma and Pharmaceutical timeline definitions:-

short term = 3 - 5 years
medium term = 5 - 10 years
long term = 10 +years

Savolitinib is the biggest opportunity globally and the fact AZ have recruited a Global Head of Commercialization for DS 1062 & Savolitinib is a great sign......

interesting development regarding their masts, I remember working at Hutchison in the days they were building out the infrastructure, supporting their IT systems.....
Their last offloading was a terrible time for Investors

Currently we are way-undervalued in my opinion. Hopefully Biden will move away from Trump's anti-China rhetoric and that may provide a better environment for U.S. listed Chinese Companies.

Lot's of news to look forward to between now and the end of the year, especially possible Surufatinib approval in China!

there will be no price at the moment as no one including the Company or the stock market knows what the price will be

My accounts are with AJ Bell (unfortunately) and they have not appeared yet, but I'm not surprised as their Corporate Actions Team are lacklustre at best.

Just over 10 years ago I bought shares in HCM for 20p, it's now 468p. It's amazing what can happen to quality small Biotech Companies if you do a decent amount of research and then take a strategic investment position. The same will happen here.

no, but they may settle your UK Ordinary share trade with ADR's, although you would never know